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Taru A. Muranen 1✉, Sofia Khan1,2, Rainer Fagerholm1, Kristiina Aittomäki3, Julie M. Cunningham 4, Joe Dennis 5, Goska Leslie 5,
Lesley McGuffog5, Michael T. Parsons 6, Jacques Simard 7, Susan Slager8, Penny Soucy7, Douglas F. Easton 5,9,
Marc Tischkowitz10,11, Amanda B. Spurdle 6, kConFab Investigators*, Rita K. Schmutzler12,13, Barbara Wappenschmidt12,13,
Eric Hahnen12,13, Maartje J. Hooning14, HEBON Investigators*, Christian F. Singer15, Gabriel Wagner15, Mads Thomassen16,
Inge Sokilde Pedersen 17,18, Susan M. Domchek19, Katherine L. Nathanson 19, Conxi Lazaro 20, Caroline Maria Rossing21,
Irene L. Andrulis 22,23, Manuel R. Teixeira 24,25, Paul James 26,27, Judy Garber28, Jeffrey N. Weitzel 29, SWE-BRCA Investigators*,
Anna Jakubowska 30,31, Drakoulis Yannoukakos 32, Esther M. John33, Melissa C. Southey34,35, Marjanka K. Schmidt 36,37,
Antonis C. Antoniou5, Georgia Chenevix-Trench6, Carl Blomqvist38,39 and Heli Nevanlinna 1
Germline genetic variation has been suggested to influence the survival of breast cancer patients independently of tumor
pathology. We have studied survival associations of genetic variants in two etiologically unique groups of breast cancer patients,
the carriers of germline pathogenic variants in BRCA1 or BRCA2 genes. We found that rs57025206 was significantly associated with
the overall survival, predicting higher mortality of BRCA1 carrier patients with estrogen receptor-negative breast cancer, with a
hazard ratio 4.37 (95% confidence interval 3.03–6.30, P= 3.1 × 10−9). Multivariable analysis adjusted for tumor characteristics
suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations
between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient
characteristics.
npj Breast Cancer            (2020) 6:44 ; https://doi.org/10.1038/s41523-020-00185-6
INTRODUCTION
Breast cancer is globally the leading cause of cancer-related
mortality for women1. The average 5-year survival rate is 83–90%
in the Western countries, substantially better than for many other
cancers, but due to its high incidence, breast cancer still leads the
statistics for cancer mortality in Europe and comes second in
North America1,2. On an individual level, prognosis varies greatly,
depending on both the inherent tumor biology and the stage of
malignant progression at diagnosis. Women with early-stage,
localized disease have a very good 5-year prognosis of ~97–99%,
but for 10–15% of women, diagnosed with locally advanced
disease, the expected 5- and 10-year survival rates range between
40–80% and 30–40%, respectively. Furthermore, the mortality
associated with metastatic breast cancer is even higher, with
median survival of <3 years2–4.
Currently, the prognosis of breast cancer patients is based on
the tumor characteristics. Gene expression and copy number
profiling5–7 or expression of marker proteins, like estrogen
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receptor (ER), progesterone receptor (PgR), human epidermal
growth factor receptor 2, and marker of proliferation Ki-67, can be
used to categorize breast cancers into biological subtypes with
specific treatment recommendations and different estimates for
patient survival8,9. Tumor grade is a histological measure of cellular
growth pattern and the best individual prognostic factor10. The
phase of tumor progression is approximated by clinical stage, which
is based on the tumor size, as well as local and systemic spread of
metastatic cells11. However, there is great variation in the survival
rates between tumors with similar characteristics and stage. This
variance has been suggested to have a heritable component,
possibly consisting of genetic differences in metastatic potential and
sensitivity to adjuvant therapy12–18. In addition, host factors, like
tumor–microenvironment interaction, immune surveillance, and
efficiency in drug metabolism may account for the genetic variability
in breast cancer patient survival19–21.
Genetic determinants of patient prognosis and the treatment
outcome prediction have been intensively sought using both
candidate gene and genome-wide approaches, but only some of
the discoveries have been successfully validated in subsequent
studies. A meta-analysis of ten genome-wide association studies
nominally validated 12 out of 45 earlier discoveries for survival
from ER-positive or any breast cancer22. Most recently, the Breast
Cancer Association Consortium (BCAC) reported two loci from
chromosome 7, based on a well-powered meta-analysis of
genome-wide association studies23.
In this study, we focused on the survival of women who carry
germline pathogenic BRCA1 or BRCA2 variants. BRCA1 and BRCA2
are the two most important breast cancer susceptibility genes,
with ~72 and 69% life-time risk of breast cancer and 44 and 17%
risk of ovarian cancer, respectively24. BRCA1/2-deficient tumors
have distinctive genomic aberration profiles, characterized by
homologous recombination deficiency25, making them stand out
as etiologically and phenotypically coherent groups of breast
carcinomas. BRCA1 risk variants are associated with high grade
and triple-negative breast cancer, which both predict poor
outcome. BRCA2 risk variants predispose primarily to ER-positive
breast cancer, but the risk of ER-negative breast cancer increases
with age26,27. Meta-analyses on the survival of women with BRCA1/
2 variants and breast cancer have suggested no significant
difference in comparison to noncarriers with phenotypically
similar tumors28–30. However, a recent study suggested ER-
positive breast cancer as an adverse indicator for cases with
BRCA2 variants, unlike for noncarriers27.
RESULTS
Tumor characteristics
We investigated genetic survival associations in pathogenic
variant carriers from the Consortium of Investigators of Modifiers
of BRCA1/2 (CIMBA), genotyped on the OncoArray31,32. Twenty-
one independent studies participating in CIMBA had survival data
available for germline carriers of pathogenic BRCA1 variants (n=
3008) and 15 studies for carriers of BRCA2 variants (n= 2,009;
Supplementary Table 1). Primarily, we analyzed patient survival in
relation to all-cause death, because this was most complete across
the participating studies. As a sensitivity analysis, the discovered
survival variants were also always assessed for breast cancer-
specific death.
Data on tumor characteristics was available for about two thirds
of patients (Table 1). The distribution of the tumor characteristics
Table 1. Tumor characteristics of the patients included in the survival analysis.
Category BRCA1 carriers n: 3008 (%) (% Missing) BRCA2 carriers n: 2009 (%) (% Missing)
ER
Negative 1510 (76.0%) 302 (22.1%)
Positive 476 (24.0%) 1067 (77.9%)
Not known 1022 (34.0%) 640 (31.9%)
PgR
Negative 1409 (80.1%) 372 (32.9%)
Positive 350 (19.9%) 759 (67.1%)
Not known 1249 (41.5%) 878 (43.7%)
Grade
1 40 (2.2%) 72 (5.8%)
2 319 (17.6%) 526 (42.6%)
3 1450 (80.2%) 636 (51.5%)
Not known 1199 (39.9%) 775 (38.6%)
T
≤2 cm 1054 (62.6%) 677 (59.0%)
2–5 cm 576 (34.2%) 421 (36.7%)
>5 cm 55 (3.3%) 50 (4.4%)
Not known 1323 (44.0%) 861 (42.9%)
N
Not affected 1305 (68.5%) 695 (53.4%)
Affected 599 (31.5%) 606 (46.6%)
Not known 1104 (36.7%) 708 (35.2%)
dg-age
Mean (sd) 41.8 (9.3) 45 (9.6)
The table summarizes the number of patients with specific recorded tumor characteristics, as well as the number of patients with no recorded data. The
proportions are given in parenthesis, so that the categories with recorded data sum to 100%, whereas the proportion in category “not known” is reported in
relation to the total of patients. dg-age was available for all patients. The last row of the table gives the average and standard deviation of the dg-age distribution.
ER estrogen receptor expression, PgR progesterone receptor expression, T tumor size category, N status of axillary lymph nodes, dg-age diagnosis age, sd standard
deviation.
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of BRCA1 and BRCA2 carriers agreed with previous reports, so that
small, high-grade, and early-onset tumors had a relatively high
frequency26,33. Tumors from BRCA1 carriers were mostly ER-
negative, while those from BRCA2 carriers were largely ER-positive.
Therefore, the main survival analyses were performed in parallel in
the following patient groups: all BRCA1 carriers, BRCA1 carriers
with ER-negative tumors, all BRCA2 carriers, and BRCA2 carriers
with ER-positive tumors.
rs57025206 predicts survival of BRCA1 carriers with ER-negative
breast cancer
We analyzed the association of germline genetic variants with the
overall survival after the first primary breast cancer diagnosis in
carriers of pathogenic BRCA1 or BRCA2 variants, using Cox
regression. The analyses were adjusted for age at breast cancer
diagnosis and stratified by country group to account for under-
lying genetic and clinical differences between populations. A
single variant, rs57025206 (minor allele frequency in European
population, MAFEUR, 0.027; info score 0.97 for imputed variant), a
nine base pair insertion in an intergenic region of 3p21.2, was
identified as a highly significant survival marker for ER-negative
breast cancer patients carrying BRCA1 pathogenic variants, with a
hazard ratio (HR) of 4.37 (95% confidence interval (CI) 3.03–6.30,
P= 3.1 × 10−9, Fig. 1). Furthermore, a multivariable analysis
adjusted for tumor grade, size, PgR expression status, and lymph
node involvement, suggested that the association is independent
of these tumor characteristics, with rs57025206-associated HR:
6.19, 95% CI: 3.73–10.3. A similar trend was observed in the
analysis of breast cancer-specific death, although the number of
patients with available data was much smaller (Supplementary
Table 2).
The survival association was specific to women with ER-
negative breast cancer, since in the analysis of all BRCA1 carriers
the HR was attenuated (HR: 2.12, 95% CI: 1.55–2.91, Supplemen-
tary Fig. 1) and not seen in those with ER-positive breast cancer
(n: 476, HR: 0.52, 95% CI: 0.17–1.60, Fig. 1c). In the analysis of
BRCA2 carriers, rs57025206 was not associated with patient
survival (HR: 0.94, 95% CI: 0.59–1.51).
The main analyses suggested nine further survival loci
We used a looser discovery threshold P-value, P < 5 × 10−7, than in
the traditional genome-wide setting to characterize loci that
potentially modify the patient survival and may form a basis for
future research hypotheses. In the analysis of the overall survival of
BRCA1 carriers, six variants exceeded the selected threshold (Table
2 and Supplementary Fig. 2). The risk magnitude was proportion-
ally associated with the number of risk alleles for two variants,
rs59010985 and rs537497819, whereas the other four variants
followed a dominant inheritance pattern. The analysis of BRCA1
carriers with ER-negative breast cancer identified four further
potential variants influencing survival (Table 2 includes also
rs57025206, presented above). No variant exceeded the signifi-
cance threshold in the analysis of BRCA2 carriers, alone. However, a
meta-analysis of BRCA1 and BRCA2 carriers (see below) suggested
germline variants associated with survival in both of these groups.
The reliability of the findings was estimated with a Bayesian
false discovery probability (BFDP) and by assessing the between-
strata (country group) heterogeneity. Ten out of the 11 BRCA1-
associated survival variants had BFDP ≤ 0.33 for at least one of
the three tested prior maximum effect sizes (Table 2). For these
ten variants, there was little heterogeneity between countries
(Supplementary Fig. 3, P against heterogeneity >0.1 for all
variants). Moreover, the variant effect sizes were consistent in
multivariable models adjusted for tumor pathologic character-
istics and in the analyses of breast cancer-associated death
(Supplementary Table 2), suggesting a consistent effect through-
out the data.
Most of the identified survival variants complied with the
proportional hazards assumption, suggesting a constant HR over
time, but rs537497819 was especially associated with poor short-
term prognosis, the effect leveling out after the first 5 years
following the diagnosis (Table 2).
Meta-analysis suggested four variants with the consistent survival
effect in BRCA1 and BRCA2 carriers
The correlation between variant effect sizes in the BRCA1 and
BRCA2 survival analyses was quite low (Pearson’s R= 0.0065 [95%
CI 0.0059–0.0072]), suggesting no overall trend for similar genetic
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Fig. 1 Survival variant rs57025206. a Kaplan–Meier plot on the
survival of ER-negative breast cancer patients carrying pathogenic
BRCA1 variants, stratified by rs57025206. b Forest plot of HR
associated with rs57025206 across country groups. (P.het: P-value
against between-study heterogeneity). c Kaplan–Meier plot on the
survival of ER-positive breast cancer patients carrying pathogenic
BRCA1 variants, stratified by rs57025206.
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survival effects in these patient groups. Nevertheless, a fixed-
effects meta-analysis highlighted four candidate variants, which
had consistent effect on patient survival in both groups (Table 3,
Supplementary Table 3 and Supplementary Fig. 4).
Four variants may have age-dependent survival effects for BRCA2
carriers
The lack of positive findings in the BRCA2-specific analyses
prompted us to consider the possibility that there may be
confounding factors, so that the genetic survival associations
would depend on tumor and patient characteristics. We had
tumor pathology data available only for a subgroup of the study
subjects, and lacked statistical power to investigate the interaction
between genetic variants and tumor characteristics. However, the
age at diagnosis was available for all cases, and to investigate
potential age-dependent genetic survival effects, we included in
the Cox regression model a covariate coded as the product of the
variant genotype and diagnosis age (continuous). The model
containing the interaction term was tested against a nested model
without interaction. Likelihood-ratio test P-values (Table 4) were
corrected for multiple testing using the Benjamini–Hochberg
method and variants with false discovery rate (FDR) ≤ 0.33 were
considered as potential discoveries. Four variants, all from the
analysis of BRCA2 carriers, passed the threshold. For illustrative
purposes, the HRs in Table 4 are presented separately for two age
groups, even though the regression model suggested that the
interaction between the variant survival effect and the diagnosis
age is continuous (Supplementary Fig. 5). The variant effect sizes
were consistent in multivariable models, including tumor patho-
logic characteristics, as well as in the analysis of breast cancer-
specific death (Supplementary Table 4).
ER-negative breast cancer is more common for postmenopausal
than premenopausal BRCA2 carriers26,33. To test whether the age-
dependent survival association of the four variants (Table 4), was a
hidden association with the tumor subtype, we analyzed the
survival separately in age- and subtype-stratified subgroups,
including only patients with data on ER expression available
(Table 1). This analysis suggested that the ER status did not explain
the age-dependent survival association. For two variants
(rs2109815 and rs35431863), the age-dependent survival associa-
tion was similar in ER-positive and ER-negative patient groups. For
the other two variants (rs372812554 and rs11255420), the survival
association did not vary by age of diagnosis in the ER-negative
patient group, and the group resembled the younger ER-positive
patient group (Supplementary Table 5).
The positional and eQTL analyses reveal potential target genes
None of the variants we found associated with survival was
located on a protein-coding region. Therefore, we took two
parallel approaches, positional and gene expression based, to
identify potential target genes. A target gene was considered to
have a strong positional evidence, if the survival variant or any
regulatory variant in linkage disequilibrium was located on an
experimentally validated enhancer of the target gene in a relevant
tissue (mammary, ovarian, blood, and adipose)34, based on the
1000 genomes and Encode data35,36. This is indicated in the Table
5, column “Positional target tissue”. If no other evidence was
available, the target gene was assumed the closest gene (no
“Positional target tissue” mentioned in Table 5). For the gene
expression-based approach, we used eQTL data from public
databases covering various human tissues and cell types
(Supplementary Data 1 and 2).
rs57025206 and its proxy variants in high linkage disequilibrium
(R2 > 0.8 in the European population, green track named “lead
variant and proxies with R2 > 0.8” in Fig. 2) are co-located with a
cluster of IQCF-genes (IQCF1–6), expressed exclusively in the testis.
These variants have eQTL associations with altogether five genesT
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in different tissues, for example, with MIR135A in adipose tissue.
However, the region does not contain annotated regulatory
elements. Furthermore, it is not in physical contact with any
transcription start site (TSS) in human mammary epithelial cells
(HMEC), suggesting that this region does not contain any HMEC-
specific enhancer (see, for example, position “g” in the heatmap of
Fig. 2). Furthermore, the MAFs of these variants range from 2.2 to
3.2% in the European population, but between 12 and 27%
globally, questioning whether the causal variant would be
rs57025206 or any of the proxies with R2 > 0.8.
The rs57025206 haploblock (with D′ > 0.8) covers a larger
genomic region with functional variants located on enhancers
regulating several protein-coding genes (turquoise and green
tracks in Fig. 2, Table 5 and Supplementary Data 1). For example,
rs56942057 (MAFEUR 0.1%, MAFGLOBAL 4.6%, D′EUR 1.0, and D′GLOBAL
0.34) and rs9824779 (MAFEUR 0.1%, MAFGLOBAL 3.9%, D′EUR 1.0, and
D′GLOBAL 0.32) are located in enhancers of DCAF1, GH03J051684,
and GH03J051668, respectively. Both variants affect conserved
sequences of transcription factor binding motifs. Furthermore, the
variant positions and DCAF1 TSS are in physical contact in HMEC
(positions “c” and “d” in Fig. 2). These two (rs56942057 and
rs9824779) and rs60497133 were eQTL variants for BAP1 in thyroid
(Supplementary Data 2), but in HMEC there was no contact
between the variant positions and BAP1 TSS (Fig. 2, positions “e”
and “f”), suggesting that the regulatory associations of these
variants and BAP1 may not exists in mammary epithelial cells. A
third potentially causal variant, rs72945708 (MAFEUR 2.0%,
MAFGLOBAL 18%, D′EUR 0.95, and D′GLOBAL 0.71), is located on a
RAD54L2 enhancer GH03J051383 and associated with the expres-
sion of GRM2 in adipose tissue. However, this variant does not
change conserved sequence of any known transcription factor
binding motif, and the topological association between the
variant locus and RAD54L2 or GRM2 TSS cannot be seen in HMEC
(positions “a” and “b” in Fig. 2, respectively). Thus, the plausible
culprit gene of the rs57025206 locus is DCAF1, an E3 ubiquitin
ligase substrate receptor targeting, e.g., TP53, ER-alpha, and EZH2.
We performed a similar target gene analysis for the 17 further
survival candidate variants (Tables 2–4) using positional and eQTL
data (Table 5 and Supplementary Data 1 and 2). For only one
variant, rs59010985, there was a single clear target gene, GAS7,
which was supported by both analyses. The majority of the other
variants could be divided into three categories. Some variants had
multiple potential target genes. For example, variants in linkage
disequilibrium with rs4879914, detected in the BRCA1–BRCA2
meta-analysis, were eQTLs for several genes in white blood cells.
Positional evidence supported the same array of target genes, in
both mammary epithelial cells and white blood cells. For some
other loci, like ASPH and CREB5, the target gene prediction was
based merely on the regulatory variants located on active
enhancers in relevant tissues, with no eQTL evidence. Further-
more, for six loci, the target gene was assumed the closest gene.
One of the 17 survival variants was located in an intergenic region
with no apparent target gene.
500 kb hg19
Functional proxies with R2<0.1 and Dprime>0.8
Functional proxies with R2>0.1 and Dprime>0.8
Lead-variant and proxies with R2>0.8
51,500,000 52,000,000 52,500,000
H3K27Ac Mark (Often Found Near Active
Regulatory Elements) on 7 cell lines
from ENCODE
Clustered interactions of
GeneHancer regulatory elements
and genes (Double Elite)
rs72945708
rs9824779
rs56942057
rs57025206
RAD54L2
DCAF1
TEX264
IQCF6
PARP3
ABHD14B
PBRM1
GPR62
RPL29 RFT1
WDR82
NT5DC2
POC1A
DUSP7
TWF2
DNAH1
STAB1
NISCHPPM1M
GLYCTK
GNL3
chr3: position (hg19)
TAD (3D genome browser)
UCSC Genes
(RefSeq, GenBank, CCDS, Rfam,
tRNAs & Comparative Genomics)
DOCK3
RRP9 DUSP7 TLR9 BAP1 NT5DC2
ABHD14B MIRLET7G SEMA3G GLT8D1
TEX264 PARP3 POC1A NISCHMANF IQCF4 PPM1M SNORD19
RBM15B GRM2 IQCF3 GPR62 GLYCTK PHF7 SMIM4 SNORD19B
IQCF1 RPL29 WDR82 TNNC1
DCAF1 IQCF5 PCBP4 BC039681 U6atac SNORD69
ACY1 LINC00696 PBRM1MIR135A1
RAD54L2 IQCF6 IQCF2 ABHD14A ALAS1 DNAH1 STAB1 GNL3
a
b
c
d
e
f
g
6
0
Fig. 2 Potential target genes on a survival locus 3p21. The heatmap visualizes the strength of association between two genomic loci in
chromosome conformation capture data from human mammary epithelial cells. The graph has been created and the topologically associated
domains (TAD) estimated with 3D genome browser, promoter.bx.psu.edu/hi-c/. The UCSC browser tracks visualize genomic annotation for the
region. The three custom tracks indicate the positions of variants in linkage disequilibrium with rs57025206. The vertical dashed lines indicate
the positions of the lead variant rs57025206 and three linked regulatory variants. UCSC genes track visualizes the positions of exons and
introns for all genes on the region. The GeneHancer track displays the interactions of distant enhancers and gene transcription start sites
(TSSs). The histone mark track shows the positions of H3K27Ac from the Encode project. In the heatmap, seven positions (a–e) have been
marked in the heatmap to indicate the probability of physical interaction between variants linked with rs57025206 and their target genes
based on positional and eQTL analysis (Supplementary Data 1 and 2) as follows: (a) RAD54L2 TSS and rs72945708 on enhancer GH03J051383
targeting RAD54L2. (b) GRM2 TSS and GRM2 eQTL variant rs72945708 on enhancer GH03J051383. (c) DCAF1 TSS and rs9824779 on enhancer
GH03J051668 targeting DCAF1. (d) DCAF1 TSS and rs56942057 on enhancer GH03J051684 targeting DCAF1. (e) BAP1 TSS and BAP1 eQTL variant
rs9824779 on enhancer GH03J051668. (f ) BAP1 TSS and BAP1 eQTL variant rs60497133. (g) MIR135A TSS and MIR135A eQTL variants rs1476290
and rs1605067.
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To detect common pathways or recurrent cellular or molecular
functions, we performed a systematic literature review (Fig. 3 and
Supplementary Table 6). Relevant literature was available for 26
out of the 40 target genes listed in Table 5, when searched from
PubMed with the keyword combinations described in the
“Methods” section. Twelve of the genes had previously been
connected with breast cancer patient survival, based on either
mRNA or protein expression, germline genetic variation, or copy
number change in mammary tumors (Fig. 3 and Supplementary
Table 6). Fourteen of the target genes were associated with
proliferative and migratory capacity of mammary or other
epithelial cells. This association was mediated via two primary
mechanisms: regulation of MAPK/ERK pathway activity or modula-
tion of cytoskeletal proteins. Target genes in two out of the four
loci associated with the survival of BRCA1 carriers with ER-negative
breast cancer (DCAF1, ZRANB1, and CTBP2) and two genes from
the BRCA1–BRCA2 meta-analysis (ZNF644 and TFCP2L1) affect the
regulation of chromatin state either directly or via polycomb
repressor complex 2 (PCR2). Eight target genes have been
suggested to affect the response to adjuvant chemotherapy,
whereas three target genes have been associated with the
response to adjuvant endocrine therapy. The latter included two
of the four loci (ASPH and GATA3) associated with age-dependent
survival effect in BRCA2 carriers. Seven genes from six loci had
been suggested to be involved in the regulation of immune
response. However, four of these genes were also associated with
regulation of mammary cell differentiation.
Comparison of the results to survival associations from a general
breast cancer population
None of the survival associations discovered in the BRCA1/2 carriers
were detected in the BCAC data of unselected and familial non-
BRCA1/2 breast cancer patients, when our results were compared
to those of Escala-Garcia et al. (Supplementary Table 7)23.
DISCUSSION
We studied germline genetic variants associated with the survival
of breast cancer patients carrying pathogenic variants in the high-
risk BRCA1 and BRCA2 genes. We identified one variant,
rs57025206, which was highly significantly associated with poor
survival of BRCA1 carriers with ER-negative breast cancer, with
HR= 4.37, 95% CI 3.03–6.30, P= 3.1 × 10−9. Furthermore, we
discovered 17 additional candidate loci, which could enhance the
understanding of the biological processes modifying the survival
of breast cancer patients and form a basis for future research. It
was noteworthy that the single significant discovery was made in
a subgroup of women with BRCA1 pathogenic variants and ER-
negative breast cancer, and this was attenuated in the wider
ARHGEF39
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RALGDS
KIF26B
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analysis of all BRCA1 carriers, because inclusion of the ER-positive
breast cancer cases, where the association did not exist, diluted
the effect in the combined analysis. Thus, the strength of the
discovery analysis came from a phenotypically homogeneous
group of cases with shared disease etiology, rather than a large
number of study subjects.
Minor alleles of two rare variants, rs9824779 and rs56942057,
are in complete linkage (D′= 1.0, R2= 0.036) with the rare, poor-
survival, allele of rs57025206. These two variants affect conserved
transcription factor binding sequences in enhancers targeting the
DCAF1 TSS, and the enhancer–TSS interaction is present in HMEC
(Fig. 2). Based on our analysis, these variants would be the best
functional candidates causing the association signal, although
their frequency was too low to allow survival analysis in the
CIMBA data.
DCAF1 is an ubiquitin ligase substrate receptor, which
recognizes and binds substrates for the CLR4 and HECT-type
ubiquitin ligases, thus regulating the substrate half-life. Further-
more, the casein kinase-like and Lis1 homology domains of the
DCAF1 protein have been shown to modulate histones by
phosphorylation and deacetylation, respectively37,38. According
to in vitro models, DCAF1 silencing reduced proliferation and
colony formation of MCF7 breast cancer and DU145 prostate
cancer cell lines39,40, whereas high DCAF1 expression blocked the
expression of tumor suppressor genes via H2A phosphorylation,
and induced a proliferative gene expression signature together
with FOXM1 (refs 38,40). In mammary epithelial progenitor cells,
DCAF1 is involved in the regulation of the Hippo pathway and ER-
alpha, contributing to the maturation of luminal and basal
lineages41.
The genomic locus of rs57025206, 3p21, is frequently deleted in
mammary carcinomas, especially in ER-negative and high-grade
tumors42–44. Subsequent research has not been able to name an
unequivocal cancer driver gene, even though several candidates
have been suggested, including BAP1 and MIR135A45,46, which
were detected as eQTL variants in our target gene analysis
(Supplementary Data 2). However, the topological data suggested
that these eQTLs might represent tissue-specific regulatory
associations not present in HMEC, and that if the rs57025206-
related survival effect is mediated via BAP1 or MIR135A, it probably
reflects host–tumor interactions.
To explore the molecular mechanisms possibly contributing to
the survival of breast cancer patients with pathological BRCA1 and
BRCA2 variants, we included in a target gene analysis and
functional literature review 17 sub-genome-wide significant
variants with reasonably low false discovery probability. Four
variants came from the BRCA1–BRCA2 meta-analysis, four variants
had age-dependent survival association for BRCA2 carriers, and the
remaining nine variants were associated with the survival of
BRCA1 carriers (Tables 2–4). With the selected thresholds for
reporting, five to six loci are expected to be false discoveries, while
the rest are likely to be true survival loci. Significant between-
strata heterogeneity was not detected for any tested variant.
A literature review of the plausible target genes indicated that
similar biological functions underscored the genetic survival
associations of BRCA1 and BRCA2 carrier breast cancer patients
(Supplementary Table 6 and Fig. 3). The most prevalent function
was the regulation of epithelial cell proliferative and migratory
capacities, suggesting that germline variants modifying the
liability of phenotypic changes in epithelial cells could be key
determinants for the outcome of breast cancer. Another interest-
ing observation was the accumulation of genes regulating
mammary epithelial cell differentiation and stemness on the loci
associated with the survival of BRCA1 carriers with ER-negative
breast cancer. In addition to DCAF1, described above, these
candidate genes include ZRANB1 and CTBP2 located on 10q26.13.
ZRANB1 is a deubiquitinase targeting, e.g., EZH2, a component of
the PRC2 and direct regulator of BRCA1 activation47,48, whereas
CTBP2 is a transcriptional corepressor priming target gene
promoters, including BRCA1, for PRC2-dependent silencing49,50.
The functional review highlighted treatment response as
another important mechanism contributing to the survival of
BRCA1/2 pathogenic variant carriers. The GATA3 locus from
the analysis of BRCA2 carriers, the TPM2/GBA2 locus from the
BRCA1–BRCA2 meta-analysis, and five out of ten loci from the
analyses of BRCA1 carriers have previously been reported to affect
the response to adjuvant chemotherapy (Supplementary Table 6
and Fig. 3). Interestingly, KIF26B, GAS7, MIR135A, and CTBP2, all
potential target genes of variants associated with the survival of
BRCA1 carriers, have been suggested to modify the response to
platinum-based chemotherapy51–56. Furthermore, CTBP2 has been
shown to affect the sensitivity to PARP inhibitors by targeting the
BRCA1 promoter for epigenetic silencing50. Platinum compounds
and PARP inhibitors are effective agents for adjuvant therapy of
BRCA1 carriers57,58. Therefore, the information on genetic variation
in these potential response-modifier loci could add to design of
targeted therapy trials.
In the analysis of BRCA2 carriers, we did not find any variants
exceeding the discovery threshold. This may be partly explained
by the smaller number of BRCA2 carriers, and consequently events,
in comparison to BRCA1 carrier analysis. However, it was intriguing
that with similar thresholds for P-value and false discovery
probability, we discovered four variants with age-dependent
survival effects. The majority of the BRCA2-related breast cancers
are hormone receptor positive (Table 1), and rely on the
endogenous supply of estrogen and possibly progesterone for
proliferation59. The level of both of these steroid hormones
decreases between the ages of 35 and 55 years60, consistent with
the diagnosis age of the majority of the BRCA2 carrier cancers in
these data (Table 1). The target gene functional review indicated
that two loci with age-dependent survival effect in BRCA2 carriers,
GATA3 and ASPH, are associated with differences in response to
adjuvant endocrine treatment61,62, further supporting the hypoth-
esis that in hormone receptor-positive breast cancer, the age-
related differences in hormone secretion and sensitivity may affect
the survival of the patients.
We can draw two conclusions from our analyses, which support
the hypothesis that the tumor etiology and subtype influence the
genetic survival associations. First, the strongest BRCA1 survival
variants were not associated with the survival of BRCA2 variant
carriers. Second, we did not find any corroboration for our
discoveries from the BCAC data (Supplementary Table 7). BRCA1
and BRCA2 carrier tumors have characteristic mutation profiles,
accompanied by homologous recombination deficiency, which
distinguishes these from unselected breast carcinomas on a
molecular level25. Notwithstanding, the mutations in these two
genes are associated with different breast cancer subtypes26,27.
Taken together, our results encourage accuracy in definition of the
outcome of interest and stringency in collecting comparable study
subjects, in order to improve the future survival studies.
Like many earlier genetic survival association studies, this study
had a limited discovery power, despite the fact that the analyzed
high-risk variant carrier cohorts were enriched with poor-
prognosis cancers, and therefore contained more events than
any equally sized cohort of unselected patients would contain.
With two phenotypically coherent groups of breast cancer
patients, which represent the largest collections of BRCA1 and
BRCA2 pathologic variant carriers in the world, we were able to
identify a single genome-wide significant locus, but were probably
underpowered to detect loci with more modest effect sizes. We
estimate that better coverage of treatment and pathology would
have greatly improved our analyses, especially as the functional
literature review suggested that the survival differences could be
mediated by differential response to adjuvant treatment. Unfortu-
nately, we did not have enough well-documented treatment data
available to test the hypothesis. The retrospective nature of our
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data brought its own limitations. The data included a notable
proportion of prevalent cases, enrolled into the participating
studies after a prolonged time period after the initial breast cancer
diagnosis. The choice of the overall survival as the basis of the
analyses impairs the clinical interpretation of the results to some
degree. However, most of the follow-up information came from
registries, and therefore the all-cause death was the best available
indicator for poor prognosis. We tried to overcome these
shortcomings with appropriate analysis methods for the prevalent
data, with posterior likelihood estimation and sensitivity analyses
with breast cancer-specific death as an end point, as well as by
testing for internal consistency.
In conclusion, we report a survival locus for BRCA1 carriers with
ER-negative breast cancer. Furthermore, the results from the
exploratory analyses suggest that the survival in women with
breast cancer is influenced by a complex action between clinical
characteristics, tumor biology, and the germline genetic
landscape.
METHODS
Study subjects
The study subjects included women of European ancestry diagnosed with
invasive breast cancer before the age of 70 years, enrolled in studies
participating in the CIMBA (Supplementary Table 1). A CIMBA study was
included in the analyses if it provided sufficient amount of follow-up data,
defined as at least 15 study subjects at risk during the time when five
events occurred. The study-wise inclusion criterion was applied separately
for the main analyses and the ER-specific subgroup analyses. This selection
yielded survival data on 3008 women carrying pathogenic germline
variants in BRCA1 from 21 studies and 2009 women carrying variants in
BRCA2 from 15 studies. Tumor characteristics of the study subjects are
provided in Table 1. The BRCA1 carriers were collected from 2664 families:
2391 families with one study subject, 220 families with two study subjects,
and 53 families with more than two study subjects. The BRCA2 carriers
were collected from 1713 families: 1486 families with one study subject,
182 families with two study subjects, and 49 families with more than two
study subjects. All participating studies were approved by their appropriate
ethics review boards, and all subjects provided informed consent.
Genotype data
The study subjects were genotyped with a custom-made array as a part of
the OncoArray project31. Details on the variant selection and data quality
control have been published elsewhere. In short, the genotyping array
included a GWAS backbone (Illumina HumanCore) and potentially cancer-
associated variants nominated by the six participating consortia. Genotyp-
ing of the CIMBA samples was conducted in six independent laboratories,
which used the same HapMap reference samples and a common
genotype-clustering file to ensure interlaboratory comparability31. The
data were imputed using the 1000 genomes as a reference panel, as
described previously32. In the analyses, we included variants with at least
60 carriers, corresponding to MAFs 0.01 and 0.015 for BRCA1 and BRCA2
carriers, respectively. This yielded data on ~9.7 million SNPs for BRCA1
carriers and 9.1 million SNPs for BRCA2 carriers.
Survival analysis
The patients were followed from the diagnosis of the first primary breast
cancer until death of any cause and censored after 15 years or when lost
from follow-up. Left truncation was applied to account for delayed study
entry. In the BRCA1 carrier analysis, the number of person years was 16,056,
the number of deaths 461, and the 15-year survival rate 0.66. The
maximum number of study subjects at risk was 1336 and this was reached
2.8 years after the baseline. The BRCA2 carrier dataset covered 10,712
person years with 311 deaths leading to a 15-year survival rate of 0.65.
Here, the highest number of study subjects at risk, 930, was reached 3.9
years after the baseline.
The genome-wide analysis of association between genetic variants and
all-cause mortality was performed with Cox regression as implemented in
the survival library of the R environment for statistical computing version
3.5.1 and 3.6.0 (refs 63–66). Linear per-allele risk model and dominant
inheritance model were estimated in parallel. Analyses were adjusted for
diagnosis age, allowing for variant–age interaction, and stratified by
country group to account for population-specific genetic and clinical
features (Supplementary Table 1). Likelihood-ratio test was used as a
measure of significant association with alpha risk P < 5 × 10−7 (two-sided).
The interaction model, i.e., Cox regression model including an interaction
term, coded as a product of the number of the effect alleles (0, 1, 2) and
diagnosis age (continuous), was tested against a nested model containing
the variant and age without interaction. Robust variance estimation was
used to account for relatedness of study subjects from the same families.
Parallel genome-wide analyses were performed also within the biologically
homogeneous patient groups: BRCA1 carriers with ER-negative tumors
(1385 patients from 17 studies, see above the study-wise inclusion criterion
for study-stratified analysis) and BRCA2 carriers with ER-positive tumors
(1050 patients from 14 studies). The results from analysis of all BRCA1 were
compared to results from analysis of all BRCA2 carriers with Pearson
correlation, and combined using a fixed-effects meta-analysis as imple-
mented in R library metafor67. For the meta-analysis, the standard errors
were recalculated using the likelihood-ratio test statistic to avoid inflation
caused by rare variants, as suggested previously23.
Using R-library powerSurvEpi68, we estimated that we had sufficient
statistical power, with the selected alpha-risk (5 × 10−7) and beta-risk 0.2,
to detect significant risk associated with common variants (MAF > 0.10), if
the HR was >1.8, whereas for rare variants (MAF 0.03–0.10), the HR should
be >2.5 for a discovery. Since we selected an alpha-level lower than the
commonly accepted genome-wide significance threshold 5 × 10−8, we
calculated a BFDP with R library gap for nominal variant effects and FDR for
the interaction models to estimate the validity of our findings69–72. In the
BFDP analysis, the prior discovery probability was set to 0.0001 and HR
alternatively to 1.3, 1.8, or 2.5, as in Escala-Garcia et al.23, and according to
the estimated thresholds for discovery from the power analyses. SNPs with
BFDP or FDR less than one-in-three were considered as interesting
discoveries.
We performed additional survival analyses for the newly discovered
SNPs only. These included multivariable survival model adjusted for tumor
pathologic characteristics and analysis of breast cancer-specific death.
Complete pathologic data were available for 1104 (36.7%) BRCA1 and 743
(37.0%) BRCA2 carriers, and the data on breast cancer-associated death for
2066 (68.7%) BRCA1 and 1591 (79.2%) BRCA2 carriers. However, data on
both pathology and cause of death were available only for 683 (22.7%)
BRCA1 and 544 (27.1%) BRCA2 carriers. The pathologic covariates in the
multivariable model were coded as follows: tumor ER expression:
categorical—no expression/positive expression (not included in the
analyses of ER-stratified patient groups); tumor PgR expression: catego-
rical—no expression/positive expression; tumor grade: linear—1, 2, 3;
tumor size: linear—1= less than 2 cm in diameter, 2= diameter between
2 cm and 5 cm, 3= larger than 5 cm in diameter; and lymph node status:
categorical—affected/not affected. The validity of the proportional hazards
assumption was evaluated for all discovered variants.
Candidate gene identification
The newly discovered survival SNPs were characterized in silico utilizing
data from the 1000 genomes35 and Encode36 projects as integrated in
databases LDlink73,74, RegulomeDB75, and GeneCards76,77. We retrieved all
short genomic variants linked with the discovered survival variants in the
1000 genomes European data with D′ > 0.8. The proxy variants were
subjected to RegulomeDB analysis and all variants with scores 1a–2f were
considered as regulatory variants potentially contributing to the survival
signal (Supplementary Data 1). The variant positions were matched to
locations of protein-coding genes and validated enhancer regions to
identify the plausibly target genes. Furthermore, we retrieved eQTL genes
from GTEx78,79 releases V6, V6p, V7, and Westra et al. blood eQTL dataset80
for all functional proxy SNPs (D′ > 0.8) and for all strongly linked proxy SNPs
(R2 > 0.8) irrespective of their functional annotation (Supplementary Data
2). The topological chromatin status at the rs57025206 locus was
investigated in Rao et al.81 data from HMEC using the 3D genome
browser82.
For a functional summary, we performed a systematic literature search
using the gene symbol and any of the keywords “breast cancer”,
“mammary”, “estrogen”, “immune”, “leukocyte”, and “lymphocyte”. If none
of these queries returned relevant publications, the search was continued
with gene symbol and “cancer” or with gene symbol alone. This was the
first stage of literature search. In the second stage, the queries consisted of
the gene symbol and any of the recurrent functional terms or interacting
proteins detected in the first stage (Fig. 3).
T.A. Muranen et al.
10
npj Breast Cancer (2020)    44 Published in partnership with the Breast Cancer Research Foundation
The survival associations of the candidate genes’ mRNA expression were
tested in the KM plotter database for breast cancer (http://kmplot.com/
analysis/)83, restricting the analysis in the relevant group of mammary
tumors: ER-negative tumors for target genes from the analyses of BRCA1
carriers, ER-positive tumors for genes from BRCA2 analysis, and all tumors
for genes from the meta-analysis. The best cutoff for the categorical
survival analysis was selected automatically and results with FDR ≤ 5%
were reported. Furthermore, the linear association between candidate
genes’ mRNA expression and patient survival was tested in the METABRIC
data (EGAD00010000434, 1302 breast cancer patients) using Cox regres-
sion. Expression data were available for 29 of the 39 candidate genes. For
each of the candidate genes, the samples were split into three categories
based on 33 and 67% percentiles of the expression values, and the
categories analyzed for 10-year overall survival. The results are included in
the functional summary in Supplementary Table 6.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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